Literature DB >> 9122711

The fibrinolytic system in neoplasia.

W R Bell1.   

Abstract

During activation of the fibrinolytic system plasminogen is converted to plasmin by tissue plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). t-PA is predominantly released from endothelial cells, u-PA primarily by renal parenchymal cells. The activation of plasminogen is regulated by plasminogen activator inhibitor-1 (PAI-1), plasmin is controlled by alpha 2-plasmin inhibitor. The fibrinolytic system is not only involved in the intravascular dissolution of fibrin (thrombi), it also plays a vital role in normal physiologic reproduction, wound repair, angiogenesis, and tissue remodeling. Fibrinolysis is also a vital component in the pathogenesis of neoplastic disease. It is essential in releasing cells from their primary site of origin, providing nutrition for neoplastic cell growth and promoting cell mobility and motility. In neoplastic cells the degradation of the extracellular matrix proteins is facilitated by excessive expression of u-PA, t-PA, and u-PAR. In many forms of carcinoma increased expression of u-PAR and u-PA is associated with significantly shorter survival. Greater expression of u-PA in breast cancer cells, for example, is associated with shorter survival and increased relapse rate. Progressively aggressive neoplastic cells evidence high expression of u-PA and u-PAR activities, variable expression of t-PA, and enhanced PAI-1 and PAI-2 activities. In acute nonlymphocytic leukemias, poor outcome correlates with high t-PA levels. In acute progranulocytic leukemia there is a high incidence of DIC. Neoplastic prostatic tissue also expresses high u-PA activity and the more aggressive the cell line, the greater the number of u-PAR and the higher the u-PA activity. In gynecologic malignancies, a greater expression of u-PA in combination with cathepsin D is associated with widespread disease and poor prognosis. High u-PA values were also seen in patients with brain, gastric, and hepatic malignancies. It is evident that the plasminogen-plasmin system is a vital component in the biology of neoplastic disease and that it is, in theses conditions, in no way beneficial to the host.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9122711     DOI: 10.1055/s-2007-999047

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  9 in total

1.  Diagnostic laparoscopy of patient with deep vein thrombosis before diagnosis of ovarian cancer: a case report.

Authors:  Jae Eun Ha; Yong Seok Lee; Hae Nam Lee; Eun Kyung Park
Journal:  Cancer Res Treat       Date:  2010-03-31       Impact factor: 4.679

2.  Expression of hypoxia-inducible factor 1alpha and cathepsin D in pituitary adenomas.

Authors:  Daizo Yoshida; Kyongsong Kim; Michio Yamazaki; Akira Teramoto
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.

Authors:  Nobuaki Nishioka; Tasuku Matsuoka; Masakazu Yashiro; Kosei Hirakawa; Kenneth Olden; John D Roberts
Journal:  Cancer Sci       Date:  2012-01-09       Impact factor: 6.716

Review 4.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

5.  Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.

Authors:  V M Díaz; M Hurtado; T M Thomson; J Reventós; R Paciucci
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

6.  [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis].

Authors:  C Aulmann; P Seufert; M Sandherr; G Schlimok; R Schulze; D Oruzio
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

7.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

Review 8.  Measuring fibrinolysis: from research to routine diagnostic assays.

Authors:  C Longstaff
Journal:  J Thromb Haemost       Date:  2018-02-17       Impact factor: 5.824

9.  Association of Preoperative Plasma D-dimmer and Fibrinogen and Renal Cell Carcinoma Outcome.

Authors:  Xiaobo He; Tao Huang; Yunfei Xue; Meng Zhang; Qiaodan Liu; Yongqiang Wang; Kai Yao; Shengjie Guo
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.